Benzodiazepine prescribing and tapering — consultant viva

Benzodiazepines are GABA-A positive allosteric modulators. Initiation requires named indication, lowest effective oral dose, shortest duration, documented review/stop date, substance and opioid/alcohol history, falls and driving counselling, and a parallel non-GABAergic plan for chronic anxiety or insomnia.[1][2][9]

Classify short–intermediate vs long-acting with active metabolites. LOT in hepatic disease: lorazepam, oxazepam, temazepam. Teaching equipotency: alprazolam ~0.5 mg ≈ diazepam 10 mg; convert chaotic short-acting high-potency use to a long-acting vehicle before stepwise cuts.[1][2][3]

Confirm actual dose; treat underlying disorder; convert if needed; reduce about 10–25% every 1–2+ weeks, slower near the end; pause for severe symptoms; reinstate cover after seizure then slower taper. Structured strategies beat abrupt advice alone.[1][3][9][10]

Sun and related data: concurrent opioids and benzodiazepines associate with overdose. Minimise combination; review both indications; counsel respiratory risk; naloxone for opioid component only.[4][2]

Beers: potentially inappropriate; Glass: unfavourable risk–benefit in older insomnia; EMPOWER education reduces inappropriate prescriptions; Canadian BRZA operationalises shared taper decisions — never abrupt-stop continuous users without a plan.[7][8][5][6]

Supportive ABC care first. Flumazenil is highly selected only — can precipitate seizures in chronic users or mixed OD; not a routine antidote or outpatient detox tool.[1][2]

Exit on day one; avoid chronic alprazolam defaults; LOT in liver; opioid synergy; 10–25% taper scaffold; EMPOWER/BRZA language; reinstate cover after withdrawal seizure.[1][4][5][9]